[go: up one dir, main page]

DE60138403D1 - Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten - Google Patents

Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten

Info

Publication number
DE60138403D1
DE60138403D1 DE60138403T DE60138403T DE60138403D1 DE 60138403 D1 DE60138403 D1 DE 60138403D1 DE 60138403 T DE60138403 T DE 60138403T DE 60138403 T DE60138403 T DE 60138403T DE 60138403 D1 DE60138403 D1 DE 60138403D1
Authority
DE
Germany
Prior art keywords
musculatory
myoblast
skeletal
genes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138403T
Other languages
English (en)
Inventor
Menzo Jans Havenga
Abraham Bout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00203336A external-priority patent/EP1191104A1/de
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE60138403D1 publication Critical patent/DE60138403D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60138403T 2000-09-26 2001-09-25 Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten Expired - Lifetime DE60138403D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23566500P 2000-09-26 2000-09-26
EP00203336A EP1191104A1 (de) 2000-09-26 2000-09-26 Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen
PCT/NL2001/000703 WO2002027006A1 (en) 2000-09-26 2001-09-25 Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts

Publications (1)

Publication Number Publication Date
DE60138403D1 true DE60138403D1 (de) 2009-05-28

Family

ID=26072717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138403T Expired - Lifetime DE60138403D1 (de) 2000-09-26 2001-09-25 Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten

Country Status (2)

Country Link
US (1) US7235233B2 (de)
DE (1) DE60138403D1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
AU2003300239A1 (en) * 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
EP2270160A1 (de) 2004-06-14 2011-01-05 Galapagos N.V. Identifizierungsverfahren und Verbindungen für die Behandlung degenerativer und entzündlicher Erkrankungen
WO2005124342A2 (en) 2004-06-21 2005-12-29 Galapagos N.V. Methods and means for treatment of osteoarthritis
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
EP2352828B1 (de) 2008-09-11 2015-02-25 Galapagos N.V. Verfahren zur identifizierung von verbindungen zur erhöhung der aktivität von cf-assoziertem mutiertem cystic fibrosis transmembrane conductance regulator (cftr)
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EP2398480A1 (de) 2009-02-19 2011-12-28 Galapagos N.V. Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
WO2010094734A2 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
JP2012517821A (ja) 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8663930B2 (en) 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
CN102724993B (zh) 2009-04-17 2016-04-27 纽约大学 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US9403891B2 (en) 2011-03-10 2016-08-02 New York University Methods and compositions for modulating TNF/TNFR signaling
JP2016518812A (ja) 2013-03-14 2016-06-30 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 線維症治療において有用な分子標的及び前記標的のインヒビター
EP2971008B1 (de) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen
WO2014139885A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
EP2972322B1 (de) 2013-03-14 2019-03-06 Galapagos NV Zielmoleküle und -verbindungen, und verfahren zur identifikation davon, zur behandlung von fibrotischen erkrankungen
CN108064275A (zh) 2014-09-24 2018-05-22 萨克生物研究学院 溶瘤肿瘤病毒及使用方法
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2000048A1 (en) 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5223394A (en) 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DK0595798T3 (da) 1989-10-20 1999-09-27 Medarex Inc Bispecifikke heteroantistoffer med dobbelte effektorfunktioner
ATE181558T1 (de) 1989-10-20 1999-07-15 Dartmouth College Iga-rezeptorspezifische monoklonale antikörper
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
DE69334238D1 (de) 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
CA2149771A1 (en) 1992-11-18 1994-05-26 Jeffrey M. Leiden Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
WO1994017832A1 (en) 1993-02-09 1994-08-18 The Scripps Research Institute Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
ATE221575T1 (de) 1993-05-10 2002-08-15 Univ Michigan Gentransfer zu den pankreatischen epithelzellen
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995006745A1 (de) 1993-09-03 1995-03-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vektor für leber-gentherapie
US5552311A (en) 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU2589695A (en) 1994-05-13 1995-12-05 Chiron Corporation Compositions and methods for targeting gene delivery vehicles
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5570975A (en) 1994-06-27 1996-11-05 Reinert, Sr.; Gary L. Metal foundation push-it and installation apparatus and method
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU705595B2 (en) 1994-09-09 1999-05-27 Neurocrine Biosciences, Incorporated Interleukin-1 type 3 receptors
FR2724846B1 (fr) 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa Methode de traitement des cancers par regulation de l'activite des proteines ras
FR2725726B1 (fr) 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
JP3565859B2 (ja) 1994-10-28 2004-09-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改良されたアデノウイルスおよびその使用法
WO1996014837A1 (en) 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
JP3351471B2 (ja) 1994-11-29 2002-11-25 タカラバイオ株式会社 形質転換細胞の製造方法
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
AUPN107195A0 (en) 1995-02-10 1995-03-09 Withers, Graham Rex Metal matrix forming method and apparatus
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2218808A1 (en) 1995-05-10 1996-11-14 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU726544B2 (en) 1995-12-08 2000-11-09 University Of Alabama At Birmingham Research Foundation, The Targeted adenovirus vectors
CA2251738A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
WO1998011221A2 (en) 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, a novel coxsackievirus and adenovirus receptor
NZ508399A (en) 1996-09-25 2003-06-30 Novartis Ag Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO1998039035A1 (en) 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
AU7250298A (en) 1997-04-25 1998-11-24 Collateral Therapeutics, Inc. Truncated vegf-related proteins
EP1015005A4 (de) 1997-05-08 2002-10-16 Genetic Therapy Inc Gentransfer mit hilfe von adenovirus enthaltend modifizierte faserproteine
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
NZ505325A (en) 1997-12-23 2003-07-25 Crucell Holland B Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
AU3358999A (en) 1998-03-20 1999-10-11 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IT1299201B1 (it) 1998-05-08 2000-02-29 San Raffaele Centro Fond Fibroblasti modificati geneticamente e loro uso
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1020529B1 (de) 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
IL133032A (en) 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1016726A1 (de) 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
DE60039683D1 (de) 1999-03-04 2008-09-11 Crucell Holland Bv Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1067188A1 (de) 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
EP1157999A1 (de) 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
EP1322774A2 (de) 2000-09-20 2003-07-02 Crucell Holland B.V. Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
EP1191104A1 (de) 2000-09-26 2002-03-27 Introgene B.V. Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen

Also Published As

Publication number Publication date
US20040071660A1 (en) 2004-04-15
US7235233B2 (en) 2007-06-26

Similar Documents

Publication Publication Date Title
DE60138403D1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
DE69900623D1 (de) Lyse von mikrobiele Zellen
DE69927556D1 (de) Flache Zellen
DE602004005387D1 (de) Zellenabstreifer
ID29767A (id) Pengisolasian zona selektif didalam sulur beralur
EP1254952A4 (de) Zellen die in der lage sind in herzmuskelzellen zu differenzieren
DE69838594D1 (de) Mehrachsige Lastzelle
DE50302985D1 (de) Kraftmesslager
ATE412726T1 (de) Reinigungsmittel für harte oberflächen
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
EP1367126A4 (de) Neue vektoren für tierzellen und verwendung davon
DE60116013D1 (de) Trennkörper für die Wälzelemente von Wälzelementführungen
DE69941869D1 (de) Spezifische gene der basalen endosperm transferzellschicht (betl)
IT1286525B1 (it) Agenti anti-incrostazione,composizioni che li contengono e loro impiego nei processi di polimerizzazione
DE69503007D1 (de) Zwischenverbindungsmaterial für elektrochemische Zellen
DE60027161D1 (de) Für das saccharose-pts-enzym ii kodierende dna
NO20033082L (no) Enkeltcelleproteinmateriale
IT1318704B1 (it) Vettori chimerici e loro uso per il trasferimento di geni eterologhi.
DE60003667D1 (de) Förderung der bildung von dialkyldihalosilanen in der direktsynthese
JP2003284553A5 (de)
SI1565562T1 (sl) Sekvenčno specifična DNK rekombinacija v eukariontskih celicah
FI20030851A7 (fi) CARD-geenistä ylävirtaan olevia sekvenssejä, niitä sisältäviä vektoreita ja niiden käyttöjä
DE60000721D1 (de) Anordnung von elektrolysezellen für die herstellung von aluminium
BR0014489B1 (pt) processo de produÇço de adenovÍrus, e, kit.
FI980782A0 (fi) En till epitel celler bindande protein region samt proteinet kodande DNA sekvens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition